Global Breast Cancer Marketplace Discussed by GBI Research in Its Report Available at MarketPublishers.com
25 Mar 2016 • by Natalie Aster
LONDON – The breast cancer pipeline emerges to be the largest one in the global pharma industry, with more than 1,040 products undergoing active development across all stage. The proportion and degree of breakthrough innovations in the pipeline is outstanding.
A large number of first-in-class products are expected to reach the marketplace in the years to come, and this will lead to transformation of the commercial and clinical landscape. Some other factors encouraging the market growth include: a large patient pool that continues growing, a well-established disease market, and more.
There are immense opportunities for co-development and in-licensing, since some 289 first-in-class products that are in development at present have not been involved in co-development and licensing deals.
In-demand research report “Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes” drawn up by GBI Research offers an up-close look at the world’s breast cancer marketplace. The study lilmelights growing opportunities biologic products have. It diversifies molecular targets and focuses on innovative first-in-class product developments. The report delves deep into clinical and commercial landscape and assesses innovations in the product pipeline. The research study explores disease causation, a signaling network and innovation alignment. It also includes first-in-class target evaluation.
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes
Published: February, 2016
Price: US$ 6,995.00
- deep analysis of innovations taking place in the breast cancer field;
- coverage of breast cancer, including its symptoms, pathophysiology, etc.;
- investigation of changing molecular target landscape between the pipeline and market;
- insights into the first-in-class therapies’ pipeline;
- valuable data on first-in-class molecular targets;
- and more.
Other diseases and disorders covered by this publisher include:
More new research studies by our market research partner are available at GBI Research page.